Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, and declined to endorse FirstCash.
Stocks · News reference
8-K filing — Sarepta Therapeutics, Inc. (SRPT)
Filed: 2026-09-23 AccNo: 0001193125-26-399416 Size: 148 KB Item 1.01: Entry into a Material Definitive Agreement
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy